摘要
结直肠癌是最常见的消化道恶性肿瘤,约10%的转移性结直肠癌(mCRC)患者携带BRAF V600E突变,携带这种突变的患者具有独特的分子特征和临床表型。其全身化疗的效果较差,对BRAF抑制剂单药不敏感,且生存率较低,因此开发新的治疗药物及临床策略以改善这些患者预后意义重大。文章阐述BRAF V600E突变mCRC的治疗方案以及合理衍生的靶向药物和免疫疗法的组合。
Colorectal cancer is the most common malignant tumor of digestive tract,and BRAF V600E mutations occur in approximately 10%of patients with metastatic colorectal cancer(mCRC).Cancer patients harboring this mutation have a unique molecular profile and clinical phenotype;they show poor response to systemic chemotherapy,insensitivity to single BRAF inhibitor,and short survival rate.It is important to develop new therapeutic agents and clinical strategies to improve the prognosis of these patients.This review mainly introduces treatment methods for BRAF V600E-mutated mCRC and rationally derived combinations of targeted agents and immunotherapy.
作者
彭炜惟
沙欢欢
方瑛
邬芝雅
周国仁
Peng Weiwei;Sha Huanhuan;Fang Ying;Wu Zhiya;Zhou Guoren(Department of Medical Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,the Affiliated Cancer Hospital of Nanjing Medical University,Nanjing 210009,China)
出处
《肿瘤研究与临床》
CAS
2024年第5期396-400,共5页
Cancer Research and Clinic
基金
国家自然科学基金(82203272)。
